vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
14.54
-1.01 (-6.50%)
At close: Jun 27, 2025, 4:00 PM
14.49
-0.05 (-0.34%)
After-hours: Jun 27, 2025, 4:04 PM EDT
vTv Therapeutics Employees
vTv Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 7 or 43.75% compared to the previous year.
Employees
23
Change (1Y)
7
Growth (1Y)
43.75%
Revenue / Employee
$739
Profits / Employee
-$812,565
Market Cap
104.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VTVT News
- 17 days ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 5 weeks ago - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - GlobeNewsWire
- 6 weeks ago - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
- 3 months ago - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - GlobeNewsWire
- 7 months ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire